Cremisi Henry D. 4

What Happened
Director Henry D. Cremisi was granted 2,500 derivative awards (stock options) on June 23, 2026. The reported acquisition price is $0.00 (grant), and no shares were sold or exercised in this filing. The grant is contingent on SEC approval to amend Daxor’s 2020 Incentive Compensation Plan.

Key Details

• Transaction date: June 23, 2026; Form filed June 25, 2026 (timely).
• Transaction type/code: A — Award/Grant of a derivative (stock options); reported price $0.00.
• Shares/options granted: 2,500.
• Vesting per filing (footnote): 833 options vest on 6/23/2026, 883 on 6/23/2027, and 834 on 6/23/2028 (amounts listed in the footnote appear to total 2,550, which differs from the 2,500 grant reported).
• Contingency: Grant is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Filed two days after the transaction date (appears timely).

Context
This entry records a grant of stock options (a derivative award), not an exercise or sale. Because the grant depends on SEC approval of a plan amendment, the options may not become effective until that approval is received. Grants are informational — they signal potential future ownership if vested and exercised but do not themselves create immediate cash proceeds or market transactions.